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Abstract
Background: South Asians have a high burden of type 2 diabetes and vascular complications. Vascular
inflammation is considered central in the pathophysiology of atherosclerosis, and the complement system is
thought to play an important role. Mannose-Binding Lectin (MBL), which activates the lectin pathway of
complement activation, has been introduced as a risk marker of vascular damage. The present study explores the
association of MBL levels, genotype and cardiovascular events in type 2 diabetic South Asians.
Methods: We conducted a prospective observational study. A cohort consisting of 168 type 2 diabetic South
Asians was followed for a median duration of 7.66 years. At baseline, MBL levels and genotype were determined.
The association with future cardiovascular events was assessed by Cox proportional hazard regression.
Results: During follow-up, 31 cardiovascular events occurred in 22 subjects (11 men, 11 women). The O/O
genotype was significantly associated with the occurrence of cardiovascular events (hazard ratio 3.42, 95%CI 1.24-
9.49, P = 0.018). However, log MBL levels were not associated with the occurrence of cardiovascular events (hazard
ratio 0.93, 95% CI 0.50-1.73).
Conclusions: In type 2 diabetic South Asians, the O/O MBL genotype is associated with cardiovascular events,
although single serum MBL levels are not.
Keywords: South Asians, type 2 diabetes, cardiovascular disease, Mannose-binding lectin (MBL)
Introduction
South Asian immigrants in Western societies have a
high burden of diabetes and vascular complications [1].
Traditional cardiovascular risk factors only partially
explain this increased risk [2]. Hence other factors must
be involved.
Atherosclerosis, the pathologic substrate of macrovas-
cular disease, is recognized to be an inflammatory pro-
cess [3]. As a player in the inflammatory response, the
complement system is thought to be involved in this
vascular inflammation [4] Indeed, complement
activation products have been demonstrated in athero-
sclerotic plaques [5].
The complement system can be activated via the clas-
sical, alternative or lectin pathway, which is activated
when Mannose-Binding Lectin (MBL) binds to its target
molecule. MBL binds carbohydrate moieties on microor-
ganisms. However, endogenous MBL ligands, such as
glycosylated immunoglobulins or cells exposed to oxida-
tive stress, have also been identified [6]. MBL serum
levels are primarily determined by 3 polymorphisms (B,
C and D genotypes, commonly referred to as O-alleles)
in the MBL gene (mbl2). Subjects with wild type MBL
genotype (A/A) have the highest serum MBL levels, sub-
jects with 1 variant allele (A/O) have intermediate levels
and subjects with 2 variant alleles (O/O) have the lowest
levels. In addition, polymorphisms in the promoter
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region influence the MBL level [7]. MBL is synthesized
in the liver. Although intraindividual levels are relatively
stable over time [8], a two-to threefold increase occurs
during acute phase reactions [9].
It has recently been suggested that MBL is involved in
the pathophysiology of cardiovascular damage in high-
risk populations [10]. In a group of type 1 diabetic Cau-
casians, MBL levels were significantly higher in subjects
with either a history of cardiovascular disease or diabetic
nephropathy compared to subjects without these vascu-
lar complications [10]. In type 2 diabetic Caucasians
high MBL levels were associated with increased mortal-
ity [11]. However, others found an association between
low MBL levels and cardiovascular events [8,12]. Data
on MBL in South Asians are lacking.
We hypothesized that MBL might be involved in the
high incidence of cardiovascular complications in type 2
diabetic South Asians. The current study aims to
explore the association of MBL levels and genotype with
cardiovascular complications in type 2 diabetic South
Asians. We demonstrate that a low MBL genotype is
associated with cardiovascular events, while a single
serum MBL level is not.
Research design and methods
Design of the follow-up study
We conducted a prospective cohort study. All studied
subjects were recruited from a previously published
study [13]. The original study population comprised 465
South Asians. At baseline, subjects that were not known
with diabetes underwent a 75 g oral glucose tolerance
test. Diabetes was diagnosed based on the ADA 2003
criteria. Out of 465 subjects, 168 subjects had type 2
diabetes at baseline (122 already known with diabetes,
46 newly diagnosed), and from these subjects follow-up
data were collected. The study protocol was approved
by the Institutional Medical Ethics Committee. All sub-
jects provided informed consent.
Study-patients were followed up by letter and subse-
quently by phone. When subjects could not be traced by
address or phone number in our database, general prac-
titioners or participating family members were involved.
Follow-up data consisted of medical history with
regard to cardiovascular events. Subjects were sent a
questionnaire and were invited for a visit to our out-
patient clinic. During this visit the questionnaire was
reviewed by the main investigator (M.A.S.). Subjects not
willing to visit the out-patient clinic were asked permis-
sion to collect medical data from their general practi-
tioner. For subjects who had died during the follow-up
period, cause of death and cardiovascular history was
retrieved from the general practitioner. All (self-)
reported events were verified by contacting the hospital
in which the event had occurred.
Measurements at baseline
Laboratory measurements at baseline included lipids,
creatinine, fasting glucose, urinary albumin/creatinine
ratio, high-sensitivity C-reactive protein (hsCRP), and
plasma SC5b-9, the soluble end product of complement
activation. Lipids, creatinine, glucose and urinary albu-
min/creatinine ratio were measured according to stan-
dard methods. High-sensitivity C-reactive protein was
measured with a fully automated Cobas Integra 800,
according to the manufacturers proceedings (Roche,
Almere, the Netherlands). The variation coefficients
(VC) were below 3%. Plasma levels of SC5b-9 were mea-
sured with an ELISA as described earlier [14].
MBL genotyping
DNA was isolated routinely from peripheral blood leu-
cocytes. MBL single nucleotide polymorphisms at
codons 52, 54 and 57 of the mbl2 gene were typed by
pyrosequencing. The detailed methodology has been
published separately [15]. The MBL genotype of only
wildtype allele carriers is designated as A/A and the pre-
sence of 1 or 2 variant alleles(s) (B, C, or D) is desig-
nated as A/O or O/O, respectively.
Serum MBL levels
At baseline, serum MBL levels were assessed by sand-
wich ELISA as described previously [16]. In brief, 96-
well ELISA plates (Greiner, Frickenhausen, Germany)
were coated with the monoclonal antibody 3E7 (mouse
IgG1 anti-MBL at 2.5 mg/ml), kindly provided by Dr.
T. Fujita (Fuhushima, Japan). Serum samples were
diluted 1/50 and 1/500 and incubated in the coated
wells. MBL was detected with Dig-conjugated 3E7.
Detection of binding of Dig-conjugated antibodies was
performed using HRP-conjugated sheep anti-Dig Abs
(Fab fragments, Roche, Mannheim, Germany). Enzyme
activity was detected using 2,2’-azino-bis(3-ethyl-
benzthiazoline-6-sulfonic acid) (Sigma Chemical Co.,
St. Louis, MO)). The optical density was measured at
415 nm using a microplate biokinetics reader (EL312e;
Biotek Instruments, Winooski, VT). A calibration line
was produced using human serum from a healthy
donor with a known concentration of MBL. Earlier
studies indicated that this assay primarily detects wild-
type MBL in serum and plasma and that there is a
direct association with the MBL genotype and with
MBL function [17].
Definition of endpoint
Cardiovascular events were defined as the occurrence of
either a myocardial infarction, Percutaneous Translum-
inal Coronary Angioplasty (PTCA), Coronary Artery
Bypass Grafting (CABG), or sudden cardiac death. The
latter was defined as a witnessed sudden circulatory
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arrest. The primary end-point was the time to the first
cardiovascular event.
Statistical analysis
Normally distributed variables are expressed as arith-
metic mean ± 1 standard deviation. Skewed distributed
variables are expressed as median with interquartile
range.
Differences between groups were assessed with the
independent samples t-test or the Mann-Whitney-U test
for normally and not-normally distributed variables
respectively. Comparison between multiple groups was
performed with analysis of variance. Correlations were
assessed by using Pearson’s correlation and Spearman’s
correlation as appropriate. Associations with cardiovas-
cular events were assessed by Cox proportional hazard
regression..All tests were two-sided and the level of sig-
nificance was set at 0.05.
All analyses were performed using SPSS Statistical
Software Package (version 17.0; SPSS, Chicago, IL)
Results
Baseline analysis
At baseline, serum MBL levels and MBL genotype were
determined in 168 diabetic subjects (122 already known
with diabetes, 46 newly diagnosed). DNA was not avail-
able in 5 diabetic patients.
The median MBL level was 476 μg/L (IQR 143-1536
μg/L). Genotype distribution in South Asians was the
same as the reported genotype distribution in Cauca-
sians [7]. MBL levels differed significantly per genotype
(P < 0.001): subjects with the A/A genotype had the
highest MBL levels (median 1300 μg/L, IQR 535-2258)
with the A/O genotype had intermediate MBL levels
(median 160 μg/L, IQR 75-295) and subjects with the
O/O genotype had the lowest MBL levels (median 74
μg/L, IQR 38-101).
MBL levels correlated weakly with BMI (r = -0.155, P
= 0.014), HbA1c (r = 0.165, P = 0.034) and hip circum-
ference (-0.169, P = 0.030), but not with sex, age, blood
pressure, high-sensitivity C-reactive protein (hsCRP),
smoking status, total cholesterol, fasting triglycerides,
and plasma SC5b-9.
Longitudinal analysis
Out of 168 type 2 diabetic subjects at baseline, 21 could
not be traced and 13 subjects refused to participate and
thus were excluded from analysis. Eighty-six subjects
visited the out-patient clinic, 31 subjects did not visit
the out-patient clinic but medical information was
retrieved from the general practitioner, and 17 subjects
had died (see below). The median duration of follow-up
was 7.66 (IQR 7.48-8.10) years. Participants lost to fol-
low-up did not differ in baseline characteristics from
participants for whom follow-up data were available
(table 1).
During follow-up, 31 cardiovascular events occurred
in 22 subjects (11 men, 11 women): 3 sudden cardiac
deaths, 2 fatal and 5 non-fatal myocardial infarction, 13
percutaneous coronary interventions, and 8 coronary
artery bypass graft procedures. Eight of these 22 subjects
had already experienced a cardiovascular event at
baseline.
Twelve subjects died due to non-cardiovascular
causes. These patients were censored, none of them
reached the primary end-point before dying.
Table 1 Baseline characteristics of the type 2 diabetic South Asian study population
Follow-up (n = 134) Lost to follow-up (n = 34) P-value
Age (years) 50.7 ± 11.2 48.9 ± 11.2 0.392
% male sex 46 45 0.886
Diabetes duration (years) 7.0 (0-13) 5.0 (0-11) 0.519
HbA1c (%) 7.7 ± 1.8 7.7 ± 2.0 0.976
Systolic blood pressure (mm Hg) 138 ± 24 140 ± 27 0.638
Diastolic blood pressure (mm Hg) 84 ± 11 84 ± 11 0.937
Urinary albumin/creatinine ratio (mg/mmol) 1.0 (0.4-4.6) 1.0 (0.4-5.0) 0.991
High-sensitivity C-reactive protein (mg/L) 3.5 (1.8-8.0) 4.8 (1.7-8.4) 0.851
Cockroft clearance (ml/min) 86 ± 27 93 ± 20 0.205
Total cholesterol (mmol/L) 5.1 ± 1.0 5.0 ± 0.9 0.666
Fasting triglycerides (mmol/L) 1.59 (1.16-2.32) 1.46 (1.24-2.13) 0.869
HDL-cholesterol (mmol/L) 1.23 ± 0.3 1.28 ± 0.3 0.954
Ratio total cholesterol: HDL-cholesterol 4.14 (3.45-5.05) 4.20 (3.10-5.0) 0.432
Body Mass Index 28.0 ± 4.7 28.4 ± 4.0 0.551
Waist-to hip ratio 0.97 (0.93-1.03) 0.99 (0.95-1.04) 0.223
% previous cardiovascular event 14 11 0.663
% current or previous smoker 45 39 0.528
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Compared to the wild-type genotype, the O/O geno-
type was significantly associated with the occurrence of
a cardiovascular event (hazard ratio 3.43, 95%CI 1.24-
9.49, P = 0.005) (table 2 and table 3 Figure 1). Subjects
with the O/O genotype did not differ in lipid parameters
or blood pressure compared to subjects with the A/A or
A/O genotype. The A/O genotype was not associated
with cardiovascular events (HR 0.65, 95% CI 0.20-2.07).
Cardiovascular events were also associated with a pre-
vious cardiovascular events (HR 4.3, 95% CI 1.2-10.3)
and log urinary albumin/creatinine ratio (HR 1.58, 95%
CI 1.0-2.48).
There was no statistically significant difference in
baseline median MBL level between subjects experien-
cing a cardiovascular event during follow-up and sub-
jects without a cardiovascular event (390 μg/L (IQR 77-
1348 μg/L) versus 466 μg/L (IQR 139-1545 μg/L), P =
0.674). Log-transformed MBL levels were not associated
with the occurrence of cardiovascular events (hazard
ratio 0.93, 95% CI 0.50-1.73). MBL levels above the
median were not associated with cardiovascular events
(hazard ratio 0.94, 95% CI 0.40-2.20). Using other MBL
cut-off levels also failed to show an association with car-
diovascular events (data not shown).
Discussion
From different parts of the world, South Asian ethnicity
has been reported to be an independent risk factor for
cardiovascular events [1,18], although survival thereafter
does not seem to be worse compared to Caucasians
[19,20]. We studied the effect of MBL genotype and
level in a group of type 2 diabetic subjects of South
Asians descent.
The main finding of the present study is that in type 2
diabetic South Asians, the O/O MBL genotype was sig-
nificantly associated with the occurrence of cardiovascu-
lar events compared to wild-type.
The association between low MBL genotype and car-
diovascular events has previously been reported in dif-
ferent populations [12,21,22]. For instance, the Strong
Heart Study included American Indians [12], which -
like South Asians-have a high burden of diabetes and
subsequent vascular complications. A low MBL geno-
type was associated with a threefold increased risk for
coronary heart disease.
With respect to serum MBL levels and cardiovascular
events, data are more controversial. Cross sectional stu-
dies found higher MBL levels in type 1 and type 2 dia-
betic Caucasians with a previous cardiovascular event
compared to diabetic subjects without cardiovascular
disease [10,11]. In non-diabetic Caucasian males but not
in females, high MBL levels were associated with future
cardiovascular events [23]. In type 2 diabetic Caucasians
high MBL levels were associated with increased all
cause mortality, although data with respect to cardiovas-
cular events were not reported [11]. In contrast, the
prospective Reykjavik study found that in type 2 diabetic
subjects low rather than high MBL levels were asso-
ciated with increased incidence of myocardial infarction
[8]. Recently, the Strong Heart Study provided data on
MBL levels, confirming that low baseline MBL levels
indeed were associated with future cardiovascular events
[24]. In our study, MBL levels were not associated with
future cardiovascular events.
A possible explanation for an association between
low MBL levels and cardiovascular events might be a
defective clearance of atherogenic particles. MBL
binds N-acetylglucosamine moieties, which are
expressed on several lipoproteins and oxidized LDL
[25], and this may facilitate their phagocytic clearance.
This hypothesis is supported by a recently published
study showing that MBL deficient subjects have
impaired clearance of triglyceride-rich lipoproteins
[26]. Additionally, MBL deficiency might influence the
Table 2 Median MBL level (interquartile range in brackets) and genotype distribution in study subjects according to
ethnicity and cardiovascular complications
Median MBL level % MBL genotype
(absolute number in brackets)
A/A A/O O/O
Cross sectional
South Asians (n = 168) 476 μg/L (143-1536) 57 (93) 35 (58) 8 (13)*
Caucasians [7] 60 36 4
Longitudinal
cardiovascular event† (n = 22) 390 μg/L (77-1348) 50 (11) 20 (4) 30 (7)‡
no cardiovascular event (112) 466 μg/L (139-1545) 56 (63) 37 (41) 7 (8)
† Cardiovascular event: see text for definition
*P = 0.226 (% O/O in South Asians compared to Caucasians)
‡ P = 0.004 (% O/O in subjects with cardiovascular event compared to subjects without cardiovascular event)
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susceptibility and course of infection with Chlamydia
pneumoniae, which is associated with coronary artery
disease [27]. On the other hand, MBL levels may
increase in the setting of an inflammatory response
[9]. Experimental studies show that in the setting of
ischemia/reperfusion high MBL levels are detrimental
rather than protective [28]. Oxidative stress induces a
change on the cellular surface [29], which results in
binding of MBL leading to enhanced complement
mediated injury. However, since MBL levels were not
correlated with plasma SC5-9 levels in our study, we
found no evidence that high MBL levels result in
increased complement activation.
Summarizing the above, whereas most cross sectional
studies found an association between cardiovascular dis-
ease and high MBL levels, most prospective studies
show an association between low MBL levels and cardi-
ovascular events.
In our study, low MBL genotype was associated with
cardiovascular events and MBL genotype corresponds
with MBL level. One would therefore expect low MBL
levels to be associated with cardiovascular events, which
however was not the case in our study. MBL genotype
probably is a more accurate estimate of cumulative
MBL exposure than a single serum MBL level. The con-
tribution of MBL to vascular disease might differ
according to the pathophysiologic phase: early in the
course low MBL levels might promote atherosclerosis,
and once a vascular inflammatory response is estab-
lished MBL levels might secondarily become increased
and - perhaps - subsequently promote vascular inflam-
mation. A recent experimental study demonstrated local
MBL synthesis in early atherosclerotic plaques [30], sup-
porting the hypothesis that MBL levels might become
increased due to atherogenesis. Based on the assumption
of time-dependency of the association between MBL
and cardiovascular disease, our single baseline sample
might have been too late in the pathophysiologic course
to detect the effect of low MBL level on cardiovascular
outcome. In addition, intra-individual variation in MBL
level and variations of the MBL assay might contribute
to the discordant findings between MBL genotype and
MBL level. Finally, at least theoretically, the association
Table 3 Association with cardiovascular events of the
MBL genotype and serum MBL level
Hazard Ratio 95% CI
MBL genotype
A/A (n = 74) 1
A/O (n = 42) 0.65 0.20-2.07
O/O (n = 13) 3.43 1.24-9.49
Combined A/O and O/O 1.26 0.52-3.04
Log MBL level (per log MBL increase)
Crude 0.93 0.50-1.73
Adjusteda 1.19 0.61-2.30
aAdjusted for urinary albumin/creatinine ratio, log high sensitivity CRP, waist-
to-hip ratio, smoking status, ratio total cholesterol: HDL-cholesterol, systolic
blood pressure, age, sex, HbA1c, diabetes duration
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Figure 1 Unadjusted Kaplan-Meier survival curves according to MBL genotype (black line = A/A (wild type), grey line = O/O
genotype). The O/O genotype has a worse event-free survival compared to the A/A genotype (Log rank test P = 0.011).
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of low MBL genotype with cardiovascular events might
be based on an association with other susceptibility
genes for cardiovascular events.
Noteworthy, although the O/O genotype was asso-
ciated with cardiovascular events, the A/0 genotype was
not, although the difference in median MBL level
between the O/O and the A/O genotype was relatively
small. However, it has previously been shown that
although MBL concentration in A/O and O/O genotype
is rather similar, functional capacity of MBL in carriers
of the O/O genotype is less compared to MBL of A/O
carriers. Functional MBL consists of polymers of 3 to 6
subunits. The number of structural variants influences
the assembly of the MBL subunits, and lower polymeri-
zation grade results in loss of function [31].
We do want to point out that the results of our study
may not apply to South Asians in general as the ances-
tors of the South Asians included in our study originally
came from a circumscriptive area in North India called
Uttar Pradesh, Uttarakhand and West-Bihar.
In conclusion, low MBL genotype is associated with
cardiovascular events in type 2 diabetic South Asians,
suggesting that MBL is involved in the pathogenesis of
cardiovascular events. However, single serum MBL con-
centrations were not associated with cardiovascular
events and therefore a single MBL level is not a clini-
cally useful risk marker for cardiovascular events in type
2 diabetic South Asians.
Abbreviations List
A/A genotype: Wild type MBL genotype; A/O genotype:
1 structural variant; HR: Hazard Ratio; MBL: Mannose-
binding Lectin; O/O genotype: 2 structural variants.
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